Literature DB >> 25630635

The effect of new drug pricing systems and new reimbursement guidelines on pharmaceutical expenditures and prescribing behavior among hypertensive patients in Korea.

Mee-Hyun Cho1, Ki-Bong Yoo2, Hoo-Yeon Lee3, Kwang-Sig Lee4, Jeoung A Kwon5, Kyu-Tae Han4, Jae-Hyun Kim4, Eun-Cheol Park6.   

Abstract

OBJECTIVE: The purpose of this study was to determine the effects of a new drug-pricing system (January 2012) and new prescription and reimbursement guidelines (January 2013) on hypertension-related pharmaceutical expenditures and prescribing behaviors in Korea.
METHODS: In all, 11,298 clinics and 2,667,132 patients with hypertension were included in our study. As dependent variables, we used the drug cost per patient, drug cost per prescribed day, number of drugs per prescription, number of prescribed days per visit, number of visits, number of original (vs. generic) drugs prescribed, and the percentage of original drug cost. Clinic characteristics and patients' age and sex were used as independent variables. Multi-level mixed-effect regression models were used.
RESULTS: The drug cost per patient decreased by -1446 KRW$ (-7.4%; p<0.001) in Q4 2012 and by -1833 (-9.3%; p<0.001) in Q2 2013 compared with Q4 2011. Number of drugs per prescription decreased significantly. The percentage of original drug cost and the number of original drugs also declined.
CONCLUSION: Reforms to the drug pricing policy and the new guidelines may reduce pharmaceutical expenditures without increasing number of drugs per prescription and the number of original drug used. Policy makers should consider the comprehensive effects of implementing new policies on both drug prices and consumption.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Antihypertensive drugs; Drug pricing system; Pharmaceutical expenditures; Pharmaceutical policy

Mesh:

Substances:

Year:  2015        PMID: 25630635     DOI: 10.1016/j.healthpol.2015.01.002

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  6 in total

1.  Cost-Effectiveness Analysis of Spending on Research and Development to Address the Needs for Innovative Therapeutic Products in Indonesia.

Authors:  Auliya A Suwantika; Angga P Kautsar; Neily Zakiyah; Rizky Abdulah; Cornelis Boersma; Maarten J Postma
Journal:  Ther Clin Risk Manag       Date:  2020-10-14       Impact factor: 2.423

2.  Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea.

Authors:  Ki-Bong Yoo; Sang Gyu Lee; Sohee Park; Tae Hyun Kim; Jeonghoon Ahn; Mee-Hyun Cho; Eun-Cheol Park
Journal:  BMJ Open       Date:  2015-07-15       Impact factor: 2.692

Review 3.  Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.

Authors:  Toon van der Gronde; Carin A Uyl-de Groot; Toine Pieters
Journal:  PLoS One       Date:  2017-08-16       Impact factor: 3.240

4.  Perception and attitude of Korean physicians towards generic drugs.

Authors:  Mikyung Ryu; Juyoung Kim
Journal:  BMC Health Serv Res       Date:  2017-08-29       Impact factor: 2.655

5.  Decomposing the effect of drug benefit program on antihypertensive medication adherence among the elderly in urban China.

Authors:  Xiaochen Ma; Yuji Zhang; Mei Zhang; Xiaoju Li; Hongpo Yin; Ke Li; Mingxia Jing
Journal:  Patient Prefer Adherence       Date:  2019-07-11       Impact factor: 2.711

6.  The speed of adoption of new drugs and prescription volume after the amendments in reimbursement coverage: the case of non-vitamin K antagonist oral anticoagulants in South Korea.

Authors:  Kyung-Bok Son
Journal:  BMC Public Health       Date:  2020-05-27       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.